Drug Trial Radar · NCT07790159
Budesonide/Formoterol Inhalation Powder in Adults With Asthma
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
338
Actual
Start
Feb 21, 2024
Primary completion
Sep 27, 2024
Study completion Nov 7, 2024
Sponsor
- Lead sponsor
- Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether budesonide/formoterol powder for inhalation (II) manufactured by Shanghai New Huanghe Pharmaceutical Co., Ltd. is non-inferior to the active comparator, Symbicort® Turbuhaler® (AstraZeneca), in the treatment of adult bronchial asthma, and to assess its safety profile in this population. The main questions it aims to answer are: Does the test product (budesonide/formoterol 160 μg/4.5 μg) show non-inferior efficacy compared to the reference product (Symbicort® Turbuhaler® 160 μg/4.5 μg) in improving lung function, as measured by the change from baseline in trough FEV1 after 42 days of treatment? What is the safety profile of the test product in adult patients with asthma? Researchers will compare participants receiving the test product plus placebo of the comparator to those receiving the active comparator plus placebo of the test product, to see if the test product is non-inferior to the reference product in terms of efficacy, with comparable safety. Participants will: Be randomized to receive either the test product (budesonide/formoterol 160 μg/4.5 μg, 2 inhalations twice daily) plus placebo of the comparator, or the active comparator (Symbicort® Turbuhaler® 160 μg/4.5 μg, 2 inhalations twice daily) plus placebo of the test product, for 6 weeks of treatment Perform daily morning and evening PEF measurements and record them, along with rescue medication use and any adverse events, in a diary card Attend regular clinic visits for pulmonary function tests, ACQ-5 and AQLQ questionnaires, safety assessments (vital signs, physical and oropharyngeal examinations, laboratory tests, and 12-lead ECG), and drug accountability
Conditions
- Asthma
Interventions
Budesonide and Formoterol FumarateDrug
Budesonide/formoterol 160 μg/4.5 μg per inhalation, administered as 2 inhalations twice daily via the Pingchuan® dry powder inhaler.
Placebo of Budesonide and Formoterol FumarateDrug
Placebo matching the test product, containing inactive excipients only, administered as 2 inhalations twice daily via the Pingchuan® dry powder inhaler.
Budesonide and Formoterol FumarateDrug
Active comparator: Symbicort® Turbuhaler® (budesonide/formoterol 160 μg/4.5 μg per inhalation), administered as 2 inhalations twice daily via the Turbuhaler® dry powder inhaler. Manufactured by AstraZeneca.
Placebo of Budesonide and Formoterol FumarateDrug
Placebo matching the active comparator (Symbicort® Turbuhaler®), containing inactive excipients only, administered as 2 inhalations twice daily via the Turbuhaler® dry powder inhaler.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in trough FEV1 after 42 days of treatmentTime frame: Baseline (Day 1 pre-dose) to Day 43
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Hefei First People's Hospital
Hefei, Anhui, China
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, China
Gansu Provincial People's Hospital
Lanzhou, Gansu, China
Huizhou Central People's Hospital
Huizhou, Guangdong, China
Guangzhou Medical University Affiliated Qingyuan Hospital (Qingyuan People's Hospital)
Qingyuan, Guangdong, China
Zhanjiang Central People's Hospital
Zhanjiang, Guangdong, China
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China
Harrison International Peace Hospital
Hengshui, Hebei, China
Hebei PetroChina Central Hospital
Langfang, Hebei, China
Daqing People's Hospital
Daqing, Heilongjiang, China
Yellow River Sanmenxia Hospital
Sanmenxia, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Yueyang Central Hospital
Yueyang, Hunan, China
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
Baotou, Inner Mongolia, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
The First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
Central Hospital Affiliated to Shenyang Medical College
Shenyang, Liaoning, China
Jinan Central Hospital
Jinan, Shandong, China
Jining First People's Hospital
Jining, Shandong, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Mianyang Central Hospital
Mianyang, Sichuan, China
Tianjin Fourth Central Hospital
Tianjin, Tianjin Municipality, China
Lishui Central Hospital
Lishui, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.